United Therapeutics Corporation Reports First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
United Therapeutics (UTHR) PT Bumped to $203 at Wedbush Despite Top-Line Miss
April 28, 2015 12:24 PM EDTWedbush analyst Liana Moussatos reiterated an Outperform rating and lifted her price target on United Therapeutics Corp. (NASDAQ: UTHR) from $198 to $203 despite Q1 results which missed on the top line.
"Despite the revenue miss, Q1 net sales for Remodulin of $146.3MM beat consensus... More
United Therapeutics (UTHR) Tops Q1 EPS by 41c
April 28, 2015 6:18 AM EDTUnited Therapeutics (NASDAQ: UTHR) reported Q1 EPS of $2.55, $0.41 better than the analyst estimate of $2.14. Revenue for the quarter came in at $327.6 million versus the consensus estimate of $353.5 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
... More